Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News aTyr Pharma Inc ATYR

Healthcare Biotechnology
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause... see more

Recent & Breaking News (NDAQ:ATYR)

aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis

GlobeNewswire 8 days ago

aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update

GlobeNewswire November 7, 2024

aTyr Pharma to Present at Upcoming Investor Conferences

GlobeNewswire October 31, 2024

aTyr Pharma to Present at the LD Micro Main Event XVII in October

Newsfile October 14, 2024

aTyr Pharma's Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting

GlobeNewswire October 8, 2024

aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal

GlobeNewswire October 2, 2024

aTyr Pharma to Participate in September Investor Conferences

GlobeNewswire August 21, 2024

aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update 

GlobeNewswire August 13, 2024

aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations

GlobeNewswire August 6, 2024

aTyr Pharma Announces Research Study with Stanford Medicine

GlobeNewswire July 30, 2024

aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT(TM) Study of Efzofitimod in Pulmonary Sarcoidosis

GlobeNewswire July 22, 2024

aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from "LIFE" to "ATYR"

GlobeNewswire June 3, 2024

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 24, 2024

aTyr Pharma to Present Poster Describing Efzofitimod's Mechanism of Action at the American Thoracic Society 2024 International Conference

GlobeNewswire May 15, 2024

aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT(TM) Study in Pulmonary Sarcoidosis

GlobeNewswire May 14, 2024

aTyr Pharma to Present at Upcoming Investor Conferences

GlobeNewswire May 6, 2024

aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update

GlobeNewswire May 2, 2024

aTyr Pharma to Participate in April Investor Conferences

GlobeNewswire April 1, 2024

aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

GlobeNewswire March 14, 2024

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results

GlobeNewswire February 28, 2024